DEBx Medical presents case studies on DEBRICHEM and discusses removal of biofilm
Rotterdam, The Netherlands, September 28, 2021 - DEBx Medical, the Dutch medical technology company revolutionizing the management of chronic wounds, announced today that the Company has presented case studies on treatment of chronic wounds during scientific congresses in Portugal and Poland. The case studies documented the deployment of DEBx Medical's innovative treatment, Debrichem(R), that initiates healing of chronic wounds by removing the biofilm.
At the conference of the Portuguese Society of Reconstructive Plastic and Aesthetic Surgery (Soceidade Portuguesa de Cirurgia Pl?stica Reconstrutiva e Estetica)[I], held from Sept 16-18th in Lisbon, Portugal, DEBx Medical's CEO Dr. Bert Quint gave a scientific talk on the Eradication of chronic wound infection within 60 seconds.
From September 21-24, the Polish Wound Society hosted The 2nd online Wound Treatment Conference.[II] In a dedicated biofilm session moderated by Dr. hab. n. med. Beate Mrozikiewics-Raikowska, DEBx Medical contributed three talks, by Prof. Gregory Schultz (Biofilm Wounds: Key Regulators in wound Inflammation) together with Bert Quint, PhD (Novel Disruptive Method eliminating biofilm and infection in a single step of 60 seconds, strongly limiting surgical debridement).
The experts agreed that health care professionals should no longer accept when wounds do not heal with a new treatment option at hand: "It is time to redefine wound healing with Debrichem. Once a wound becomes chronic and contains a biofilm, thorough debridement is the first step in the treatment plan. The biofilm and its embedded infection need to be completely removed to allow the healing process to start again," said Gregory Schultz, PhD, Professor Emeritus of Obstetrics and Gynecology at the University of Florida, USA. "Debrichem is an effective novel agent and an alternative for surgical debridement, allowing for most wounds to start healing after only one treatment. Debridement with Debrichem is based on desiccation of the proteins and pathogens in the wound bed, which is a new and very promising solution to simplify the treatment of chronic wounds."
All cases presented during the conferences demonstrated the onset of the healing process, emphasizing the effectiveness of Debrichem. The debriding agent has been shown to effectively remove the biofilm in vitro. So far, there has been clinical experience of almost 3,000 wounds that have been treated with Debrichem. Most wounds started healing after only one treatment with Debrichem, irrespective of the size or condition of the wound, provided that there is restored perfusion present in and around the wound.
Chronic wounds have a prevalence of up to 2 % in the general population. The outcome depends on the wound etiology, with arterial ulcers and venous leg ulcers having especially low healing rates. To no surprise, general quality of life is impaired in patients with chronic wounds. Wounds are called chronic if they have not healed, at least in part, within 4 to 12 weeks. In the physiological healing process, granulation is considered the first step. Biofilm has been identified in 80 % of non-healing wounds, caused by different bacterial strains. The presence of a bacterial biofilm makes antibiotics less effective. The current gold standard treatment is surgical debridement to disrupt the biofilm, requires the sterile environment of an operational theater. Surgical debridement does not, however, reliably initiate healing of the wound and is often part of an extensive wound management program requiring patients to repeatedly come to the hospital. The economic burden of chronic wounds is substantial, exacerbated by amputations especially for diabetic foot ulcers of up to 34 % (pre-Covid-19 pandemic). In the UK alone, chronic wounds generated costs of GBP 5.6 bn in 2018. The total wound care costs in the UK increased annually by 8 to 9 % with chronic wounds accounting for the largest share. Increasing evidence points to the fact that the COVID-19 pandemic has led to a serious delay in treatment of chronic wounds, leading to a 'pandemic within the pandemic'.
DEBx Medical plans to participate in upcoming scientific congresses
EWMA (European Wound Management Association) virtual conference[III] October 26 - 27, 2021 SAWC Fall (Symposium on Advanced Wound Care)[IV] October 29 - 31, 2021, Las Vegas, USA Wounds UK Annual Conference 2021[V] November 8 - 10, 2021, Harrogate, UK XVI Congresso Nazionale AIUC[VI] November 17 - 20, 2021, Rome, Italy N?rnberger Wundkongress[VII] December 2 - 3, Nuremberg, GER More details on talks, abstracts and attending company representatives can be obtained online and on LinkedIn. Please follow us, and we are looking forward to meeting you at the congresses. ?
About DEBx Medical DEBx Medical B.V. is a Dutch medical technology company dedicated to revolutionizing the management of chronic wounds by enabling their healing, thereby improving the outcomes for millions of patients. DEBx Medical aims to support doctors and their patients from diagnosis through treatment, follow-up care and maintenance of a healthy wound bed. The Company focuses its pipeline on targeting pathogens that corrupt wound healing, aiming to deliver affordable and effective treatment approaches that can easily be applied and implemented in daily clinical practice. DEBx Medical is commercializing Debrichem(R) through a worldwide network of distributors, with the first market launches in Italy, Portugal and Poland.
Contact: DEBx Medical B.V. Anne Marieke Ezendam, Strategic Communicationsemail@example.com Media Relations: MC Services AG Eva Bauer / Dr. Brigitte Keller phone: +49 89 210 228 firstname.lastname@example.org ?
References [I]https://spcpre.pt[II] https://www.termedia.pl/Konferencja-II-Miedzynarodowa-Konferencja-Polskiego-Towarzystwa-Intro,1438,12784.html[III]https://ewma.org/ewma-conferences/conference-information[IV]https://www.sawcfall.com/[V]https://live.wounds-uk.com/wounds-annual-2021/[VI]http://www.aiuc.it/pagina/764/xvi+congresso+nazionale+aiuc[VI]https://www.wuko2021.de/ Malone M et al., J Wound Care 2017;26(1):20-25. https://doi.org/10.12968/jowc.2017.26.1.20 Schwarzer S et al., Int J Mol Sci 2021;22:9471. https://doi.org/10.3390/ijms22179471 Martinengo L et al., Ann Epidemiol 2019;29:8-15. https://doi.org/10.1016/j.annepidem.2018.10.005 McCosker L et al., Int Wound J 2019;16:84-95. https://doi.org/10.1111/iwj.12996 Olsen M et al., Wound Repair Regen 2019;27(1):114-125. https://doi.org/10.1111/wrr.12683http://www.shieldhealthcare.com/community/popular/2015/12/18/how-wounds-heal-the-4-main-phases-of-wound-healing/ Guest JF et al., BMJ Open 2020;10:e045253. https://doi.org/10.1136/bmjopen-2020-045253 Armstrong DG, AJMC Sep 21; https://www.ajmc.com/view/managing-the-surge-delayed-chronic-wound-care-during-covid-19
28.09.2021 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.deLanguage: English Company: DEBx Medical B.V. Boompjes 40 3011 XB Rotterdam
Netherlands Phone: +31 107986950 E-mail: email@example.com Internet: www.debx-medical.com EQS News ID: 1236307 ? End of News DGAP News Service